Phase IIb trial shows a personalized mRNA vaccine significantly lowers melanoma risk, suggesting future efficacy.
Five-year data from the phase IIb KEYNOTE-942 study show that the mRNA-based neoantigen vaccine intismeran autogene continues to reduce the risk of melanoma recurrence or death by roughly 49% when combined with pembrolizumab. This durability strengthens confidence in the personalized vaccine strategy, but a larger phase III trial will provide the decisive findings.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: